Company Overview

ENDRA Life Sciences Inc. is a U.S.-based medical technology company focused on the development of advanced ultrasound imaging technologies designed to improve the detection and management of metabolic and liver-related diseases. The company operates within the medical device, diagnostic imaging, and digital health industries, with a primary emphasis on non-invasive imaging solutions for assessing tissue composition and liver health. ENDRA’s core technology platform is Thermo Acoustic Enhanced UltraSound (TAEUS®), which is designed to enhance conventional ultrasound by enabling clinicians to visualize and measure tissue characteristics that are difficult to detect using standard ultrasound alone.

The company’s principal commercial objective has centered on the use of TAEUS® for the assessment of fatty liver disease, including non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD). ENDRA positions its technology as a lower-cost, more accessible alternative to MRI-based liver fat quantification systems. Founded in 2007 and headquartered in Ann Arbor, Michigan, the company evolved from an early-stage imaging technology developer into a publicly traded medical device company listed on Nasdaq under the ticker NDRA. Its strategic positioning has focused on integrating its imaging platform with existing ultrasound systems rather than requiring entirely new imaging infrastructure.

Business Operations

ENDRA’s operations are primarily centered on the development, validation, regulatory advancement, and commercialization planning of its TAEUS® imaging platform. The company has historically operated as a single-segment business focused on research and development activities, intellectual property generation, clinical validation studies, and collaboration with healthcare institutions and ultrasound equipment manufacturers. Revenue generation has remained limited, with the company largely dependent on financing activities and strategic development initiatives while advancing toward broader commercialization.

The company’s technology portfolio includes proprietary thermoacoustic imaging methods, software algorithms, and associated imaging system components intended to work alongside conventional ultrasound equipment. ENDRA has pursued collaborations with clinical research centers and imaging partners to support validation studies and regulatory submissions. The company maintains intellectual property related to thermoacoustic imaging and quantitative tissue characterization technologies. Operations have largely been concentrated in the United States, though the company has also pursued relationships and evaluations involving international medical institutions and imaging markets.

Strategic Position & Investments

ENDRA’s strategic direction has focused on addressing the growing global prevalence of liver disease and metabolic disorders by offering a scalable and lower-cost imaging alternative to MRI-based diagnostics. The company has emphasized the clinical and economic benefits of integrating its technology into existing ultrasound workflows, which could potentially expand access to liver fat assessment in primary care and outpatient settings. Its growth initiatives have included clinical studies, regulatory engagement, software and hardware refinement, and efforts to establish commercial partnerships within the ultrasound ecosystem.

The company has invested substantially in the advancement of its proprietary TAEUS® platform, including clinical validation programs and intellectual property development. ENDRA’s activities have also reflected broader trends in precision diagnostics, AI-enabled imaging interpretation, and non-invasive disease monitoring. Public disclosures and regulatory filings indicate continued focus on obtaining broader clinical adoption and regulatory clearances while strengthening strategic relationships within the medical imaging sector. Data regarding large-scale acquisitions or extensive subsidiary portfolios is inconclusive based on available public sources.

Geographic Footprint

ENDRA Life Sciences maintains its headquarters in Ann Arbor, Michigan, and its operational footprint has primarily been concentrated in the United States. The company’s research, development, regulatory, and administrative activities have largely been managed domestically, with collaborations involving U.S.-based clinical and imaging institutions playing a significant role in product development and validation efforts.

Although ENDRA’s direct commercial presence outside the United States has been limited, the company has positioned its technology for potential applicability across international healthcare markets where liver disease prevalence is increasing. Public filings and company disclosures reference engagement with global medical imaging stakeholders and the broader international ultrasound market, including opportunities in Europe and Asia-Pacific, where demand for cost-effective diagnostic imaging tools continues to expand.

Leadership & Governance

ENDRA Life Sciences is led by executives with backgrounds in medical devices, imaging technology, commercialization, and corporate finance. The company’s leadership strategy has emphasized technological innovation, regulatory advancement, and the pursuit of strategic industry partnerships aimed at supporting long-term commercialization of the TAEUS® platform. Governance oversight is provided through its executive leadership team and board of directors in accordance with Nasdaq-listed company requirements and applicable SEC reporting standards.

Key executives include:

• Alexander Tokman – Chief Executive Officer
• Michael Thornton – Chief Financial Officer
• R. Michael Dolphin – Director
• Francis K. Hefti, Ph.D. – Director
• David Wells – Director

The company’s leadership has consistently communicated a strategic vision centered on improving accessibility to advanced liver diagnostics through integration with conventional ultrasound systems rather than relying on high-cost standalone imaging modalities. Public statements and regulatory filings indicate a continued focus on clinical evidence generation, commercialization readiness, and shareholder-funded technology development initiatives.